SymbolELOX
NameELOXX PHARMACEUTICALS, INC.
SectorUNDEFINED
RegionNorth America
Industry-
Address02476 United States MA P.O. Box 274
Telephone(781) 577-5300
Fax
Email
Websitehttp://www.eloxxpharma.com/
IncorporationUS
Incorporated On1999
Employees
Fiscal Year6/30
Public Since
ExchangesOTC;NASDAQ
AuditorErnst & Young LLP;
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001035354
Description

The primary business of the Company is to utilize our patented and patent-pending technology related to antibody genes, antibody discovery technology, modified cow antibodies, and antibody drug candidates, and related technologies for human therapeutic applications to develop novel approaches to treat cancer and inflammatory diseases.

Additional info from OTC:
The primary business of the Company is to utilize our patented and patent-pending technology related to antibody genes, antibody discovery technology, modified cow antibodies, and antibody drug candidates, and related technologies for human therapeutic applications to develop novel approaches to treat cancer and inflammatory diseases.

2025-08-14 20:03

New Form NT 10-Q - Eloxx Pharmaceuticals, Inc. Filed: 2025-08-14 AccNo: 0001104659-25-078543 Size: 32 KB

Read more
2025-08-12 21:23

(99% Neutral) Eloxx Pharmaceuticals, Inc. (ELOX) Announces Executive Departure

Read more
2025-05-15 20:02

New Form NT 10-Q - Eloxx Pharmaceuticals, Inc. Filed: 2025-05-15 AccNo: 0001104659-25-049378 Size: 35 KB

Read more
2025-04-01 20:06

New Form NT 10-K - Eloxx Pharmaceuticals, Inc. Filed: 2025-04-01 AccNo: 0001104659-25-030543 Size: 32 KB

Read more
2025-02-21 15:00

New Form SEC STAFF ACTION - Eloxx Pharmaceuticals, Inc. Filed: 2025-02-21 AccNo: 9999999997-25-000521 Size: 4 KB

Read more
2025-01-28 22:37

Director Aggarwal Sumit 🟡 adjusted position in 0 shares (1 derivative) of Eloxx Pharmaceuticals, Inc. (ELOX) Transaction Date: Jan 24, 2025 | Filing ID: 006784

Read more
2025-01-28 22:36

Director Rubin Steven D 🟡 adjusted position in 0 shares (1 derivative) of Eloxx Pharmaceuticals, Inc. (ELOX) Transaction Date: Jan 24, 2025 | Filing ID: 006783

Read more
2025-01-28 22:36

Director Androski Lindsay 🟡 adjusted position in 0 shares (1 derivative) of Eloxx Pharmaceuticals, Inc. (ELOX) Transaction Date: Jan 24, 2025 | Filing ID: 006782

Read more
2025-01-28 22:35

Director Walts Alan Edmund 🟡 adjusted position in 0 shares (1 derivative) of Eloxx Pharmaceuticals, Inc. (ELOX) Transaction Date: Jan 24, 2025 | Filing ID: 006781

Read more
2024-11-19 21:01

New Form NT 10-Q - Eloxx Pharmaceuticals, Inc. Filed: 2024-11-19 AccNo: 0001104659-24-120555 Size: 37 KB

Read more